This cluster is routine — all sales follow option vesting/exercise events and are immaterial by dollar size. No bearish read-through. Monitor next earnings (likely catalyst) or any material clinical update given the biotech sector context. The 95% analyst bullish consensus remains unchanged.
Price Chart
Executive Summary
Multiple Dianthus Therapeutics insiders, including CEO Marino and GC Veness, executed open-market sales totaling $3.15M over a 7-day window, with $1.12M (CEO) and $1.78M (GC) concentrated on a single day. The sales are likely liquidity-driven following vesting and option exercises (non-cash derivatives), but the CEO's involvement and total value relative to the $6.5B market cap (0.048%) suggests routine portfolio diversification rather than a bearish signal.
Key Financial Metrics
Key Facts
- 4 insiders sold a total of ~$3.15M in open-market transactions from Aug 7-10, 2026.
- CEO Marino sold 10.4K shares at $107.49 for $1.12M on Aug 7.
- GC Veness sold 16.2K shares at $110.38 for $1.78M on Aug 10.
- Total insider sales represent 0.048% of $6.5B market cap — well below any material threshold.
- All sales coincided with option exercises (non-cash derivative exercise events on the same dates).
- Historical calibration: past bullish calls on DNTH had strong T+20 win rate (70%) with average alpha +3.19%.
- Score calibration suggests impactScore 6 has ~54% observedP in this segment, but 0.048% of market cap is trivial.
Financial Impact
Total insider sales of $3.15M represent less than 0.05% of market cap — economically insignificant.
Risk Factors
- No open-market buys from any insider to counterbalance selling.
- If stock declines >10%, the lack of insider buying could amplify selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-DNTH-1786775156334 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access